Sangamo Therapeutics, Inc.
NASDAQ:SGMO · NASDAQ Global Select
+$0.00 today
Vol 0.50M · Avg 9.89M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
861.6%
avg -14.5%
ROIC
-566.4%
avg -107.1%
ROA
-205.8%
avg -58.1%
Analysis
ROE is currently the strongest return metric at 861.6% versus its period average of -14.5%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Alexander D. Macrae Ch.B MRCP | Chief Executive Officer, President & Director | $930,255.00 | — | 63 | $1.90M | 0.46% |
Nathalie Dubois-Stringfellow | Senior Vice President & Chief Development Officer | $585,224.00 | — | 64 | $328,733.00 | 0.08% |
Scott Willoughby | Senior Vice President, Chief Legal Officer & Corporate Secretary | $569,651.00 | — | 51 | $647,370.00 | 0.16% |
Gregory Davis | Head of Research & Technology | — | — | 56 | $113,654.00 | 0.03% |
Louise Wilkie | Head of Global Corporate Communications & Investor Relations | — | — | — | — | — |
David Ojala | Scientist II - Discovery & Translational Research | — | — | — | $212,471.00 | 0.05% |
Nikunj Jain | Interim CFO and Principal Financial & Accounting Officer | — | — | 46 | $235,292.00 | 0.06% |
Phillip Ramsey | Chief Technical Officer | — | — | — | — | — |
Stephanie J. Seiler | Vice President and Head of Business Development & Alliance Management | — | — | — | $99,600.00 | 0.02% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$106,878.01
Net Sentiment
$106,878.01
Net selling
Most Active
Davis Gregory D
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Apr 22, 2026 | Davis Gregory D Direct | Sell | 69.8K | $0.25 | $17,694.16 | |
| Apr 21, 2026 | Dubois-Stringfellow Nathalie Direct | Sell | 345.9K | $0.26 | $89,183.85 |
Analysis
Insiders reported 0 buys worth $0.00 and 2 sells worth $106,878.01 over the last 12 months. That adds up to net selling of $106,878.01. Davis Gregory D was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +22.2% | +19.0% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +22.2% over three years. Forward estimates point to Revenue at +19.0% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
C4 Therapeutics, Inc.
NASDAQ:CCCC
$323.03M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
Innate Pharma S.A.
NASDAQ:IPHA
$165.27M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
$150.58M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$49.65M
Who manages SGMO?
Sangamo Therapeutics, Inc. (SGMO) lists 9 active executives. The top listed executive is Gregory Davis, Head of Research & Technology.
Are SGMO insiders buying or selling?
Recent insider activity shows net selling of $815,851.32.
Explore More
Continue the stock analysis
Jump to another research area for this company.